Vistagen Therapeutics, Inc. filed a Form 8-K on October 30, 2026, disclosing a Board-approved reduction in workforce of approximately 31%, effective October 26, 2026, with estimated severance costs of approximately $1.0 million and projected annual salary and benefits savings of approximately $3.2 million.

Key Highlights

  • Workforce reduction: Vistagen implemented a Board-approved reduction in workforce of approximately 31%, effective October 26, 2026.
  • Severance costs: The company estimates it will incur severance and termination costs of approximately $1.0 million.
  • Projected savings: The reduction is expected to save approximately $3.2 million in salary and benefits annually.
  • Retained capabilities: The company disclosed it is retaining core clinical, regulatory, technical, and corporate capabilities required for U.S. registration-directed Phase 3 development of fasedienol.
  • Lead programs: Fasedienol targets social anxiety disorder; itruvone targets major depressive disorder; refisolone targets menopausal hot flashes, according to the filing.
  • Severance eligibility: Affected employees may receive cash severance and temporary healthcare coverage if they enter into an effective separation agreement including a general release of claims against the company.

Vistagen Details October 2026 Workforce Reduction and Cost Structure Changes

According to the filing, Vistagen Therapeutics, Inc. (NASDAQ:VTGN) implemented the workforce reduction on October 26, 2026, following Board approval. The company disclosed that the action is "intended to reduce operating expenses, preserve capital with cost efficiencies, and align the size and structure of its workforce with its late clinical-stage priorities." The retained workforce is intended to support Phase 3 development of fasedienol, the company's lead clinical-stage product candidate for social anxiety disorder, as well as potential future development of itruvone for major depressive disorder and refisolone for menopausal hot flashes.

The filing states that affected employees may be eligible for cash severance and temporary healthcare coverage, contingent on entering into an effective separation agreement that includes a general release of claims against the company. Vistagen estimates severance and termination costs of approximately $1.0 million, and expects the reduction to generate approximately $3.2 million in annual salary and benefits savings. The company also noted it "may incur additional costs not currently contemplated due to events that may occur because of, or that are associated with, the reduction in its workforce."

The filing includes forward-looking statements regarding estimated costs and savings, and the company cautioned that these estimates are subject to a number of assumptions and that "actual results may differ materially from these estimates." The company referenced risk factors in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, and its Quarterly Report on Form 10-Q for the period ended June 30, 2026, as sources of additional risks that may affect outcomes. The report was signed by Shawn K. Singh, President and Chief Executive Officer, on October 30, 2026.

What Was Disclosed

Vistagen disclosed a roughly 31% workforce reduction effective October 26, 2026, with estimated severance costs of approximately $1.0 million and projected annual savings of approximately $3.2 million in salary and benefits, aimed at aligning the company with its Phase 3 clinical priorities.